One-Third Of Her2 Positive Patients Have 80-Gene Luminal Subtype That Is Resistant To Chemo-Trastuzumab But Sensitive To Chemo-Trastuzumab-Pertuzumab: Critical Implications For The Adjuvant Setting From The Nbrst Phase 4 Neoadjuvant Study